With fo­cus on ne­glect­ed eye dis­eases, Opus buys two gene ther­a­pies from Iver­ic Bio

A seed-stage biotech found­ed by Lux­tur­na’s in­ven­tor has ac­quired two gene ther­a­py prod­ucts from a biotech that just sub­mit­ted an NDA.

Opus Ge­net­ics paid Iver­ic Bio $500,000 up­front to snag the rights to two pre­clin­i­cal pro­grams for rare reti­nal dis­eases, the fledg­ling biotech said Wednes­day. Iver­ic, which re­cent­ly fin­ished up an NDA fil­ing for its ge­o­graph­ic at­ro­phy drug, al­so se­cures some­where be­tween 5% and 9.9% own­er­ship of Opus, as well as the po­ten­tial for biobucks and “low sin­gle-dig­it earnout” on net sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER